• Wook Jeong, Hsichiang Kung, Chia Chi Cheng, Changwoo Lim, Min Jung Jung, Jaeho Lee, Doo Sik Kim, and Yusom Shin.
• Department of Anesthesiology and Pain Medicine, Suryeoan Clinic, Busan, Republic of Korea.
• Pain Res Manag. 2017 Jan 1; 2017: 9045608.

BackgroundSeveral studies have shown that dexmedetomidine (DXM), a selective α2-adrenoceptor agonist, also has neuroprotective effects. However, its effect on impaired peripheral nerve regeneration has not been studied.Materials And MethodsForty-five Sprague-Dawley rats were randomly assigned to three groups: group 1 (control SHAM), group 2 (sciatic nerve injury + normal saline), and group 3 (sciatic nerve injury + DXM). The rats of group 3 were subdivided into the following three groups: DXM 0.5, 6, and 20 μg·kg-1 (groups 3A, 3B, and 3C, resp.). The sciatic nerve injury was assessed for nerve regeneration at 2 and 6 weeks.ResultsThere were no differences between groups 2 and 3 in their sciatic functional index (SFI) values or histological findings at 2 weeks postinjury. However, SFI differences were statistically significant at 6 weeks postinjury in group 3. The gross findings with H&E staining showed that the number of axons was higher in group 3 than in group 2. There was no histological difference according to the DXM concentration.ConclusionThe coincidental functional and histological assessment results of this study suggest that DXM for 6 weeks positively affects damaged peripheral nerves.

22 keywords...

hide…